Cadence’s omiganan pentahydrochloride (Omigard) has failed. That’s it. Dead. It’s over. The peptide failed to demonstrate superiority over iodine in preventing patients from getting infections at the site of catheter injections.

Omiganan was licensed from Migenix back in 2004 in a $30M ($2.65M upfront) deal. Cadence spent between nearly $100M to get the product to this stage. Now that it’s kaput, the company plans to “restructure” which “may include a workforce reduction.”

CEO Ted Schroeder had this to say:

“While we are disappointed in the outcome, we are confident that the trial was conducted in a high-quality manner. We believe that we can best drive both near and long-term value by focusing our resources on our lead product candidate, Acetavance.”

Acetavance is an i.v. version of acetaminophen which is marketed with BMS. Cutanea Life Sciences is developing a topical version of Omiganan for rosacea and acne.

Read more from Xconomy.

Image from treehugger

Related Posts